Skip to content

PMN

ProMIS Neurosciences, Inc.

NASDAQ · Healthcare · Biotechnology · CA

$8.23
+0.98%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
-54.7%
EPS
—
Free cash flow
-77.3%
Operating cash flow
-77.3%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
+76.1%

Three-year CAGR

Revenue
—
EBITDA
—
EBIT
—
Net income
—
EPS
—
Free cash flow
-3.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026